Portfolio data

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa

• Late-stage clinical companies
• Beacon Therapeutics

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

• Late-stage clinical companies
• Autolus Therapeutics

Beacon Announces Unmasked Three-Month Data from Phase 2 SKYLINE Trial of AGTC-501 for X-Linked Retinitis Pigmentosa

• Late-stage clinical companies
• Beacon Therapeutics

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

• Late-stage clinical companies
• Autolus Therapeutics

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress